BELLUS HEALTH INC

Share · CA07987C2040 · BLU · A2PQKK (XTSE)

No Price

n/a

Company Profile for BELLUS HEALTH INC Share

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

AI Analysis of BELLUS HEALTH INC

Click any analysis below to get instant AI insights from finAgent

Company Data

Name BELLUS HEALTH INC

Company BELLUS Health Inc.

Symbol BLU

Website https://www.bellushealth.com

Primary Exchange

TSX

WKN A2PQKK

ISIN CA07987C2040

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Roberto Francesco Bellini

Market Capitalization 2 Mrd.

Country Canada

Currency CAD

Employees 0,1 T

Address 275 Armand-Frappier Boulevard, H7V 4A7 Laval

IPO Date 2000-10-27

Stock Splits

Date	Split
19.08.2019	277:1000
29.05.2012	1:30

ID Changes

Date	From	To
31.03.2008	NRMX	BLU

Ticker Symbols

Name	Symbol
NASDAQ	BLU

More Shares

Investors who hold BELLUS HEALTH INC also have the following shares in their portfolio:

3D SYSTEMS CORP Share

AMAZON.CO INC Share

COSTCO WHOLESALE CORP Share

GLOBAL SHORT-TERM CORPRATE BOND INDEX FUND - EUR HEDGED ACC Fund

ISHARES PHYS.MET.O.END ZT ETC

ISHSIII-M.W.S.C.U.ETF DLA ETF

MICROSOFT CORP Share

NETWORK R.I.FIN.07/37 MTN Bond

Novo Nordisk Share

PALANTIR TECHNOLOGIESLOGIES INC CLASS A Share

TENCENT . LTD Share

TESLA INC Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog